Were Analysts Bullish China Cord Blood Corporation (NYSE:CO) This Week?

December 8, 2017 - By Clifton Ray

 Were Analysts Bullish China Cord Blood Corporation (NYSE:CO) This Week?
Investors sentiment increased to 2.33 in 2017 Q2. Its up 0.89, from 1.44 in 2017Q1. It improved, as 4 investors sold China Cord Blood Corporation shares while 5 reduced holdings. 15 funds opened positions while 6 raised stakes. 6.75 million shares or 4.83% more from 6.44 million shares in 2017Q1 were reported.
Citigroup has invested 0% in China Cord Blood Corporation (NYSE:CO). Creative Planning reported 400 shares. Us Bank De invested 0% in China Cord Blood Corporation (NYSE:CO). California Employees Retirement invested 0% of its portfolio in China Cord Blood Corporation (NYSE:CO). Acadian Asset Mgmt Limited Liability Company owns 0.03% invested in China Cord Blood Corporation (NYSE:CO) for 622,995 shares. The Illinois-based Peak6 L P has invested 0.01% in China Cord Blood Corporation (NYSE:CO). National Bank & Trust Of Montreal Can invested in 0% or 1,000 shares. Glg Partners L P holds 0.79% of its portfolio in China Cord Blood Corporation (NYSE:CO) for 1.51M shares. Sg Americas Ltd Liability Com has invested 0.01% in China Cord Blood Corporation (NYSE:CO). Moreover, Brandes Ptnrs Lp has 0.01% invested in China Cord Blood Corporation (NYSE:CO). Moreover, Fny Managed Accounts Ltd Liability Company has 0.03% invested in China Cord Blood Corporation (NYSE:CO) for 350 shares. Rock Springs Cap Mngmt Ltd Partnership has invested 0.42% in China Cord Blood Corporation (NYSE:CO). Renaissance Technology Limited Liability Company holds 1.15 million shares. Barclays Public Ltd Com invested in 2,000 shares. Parametric Associate Lc has 0% invested in China Cord Blood Corporation (NYSE:CO).

China Cord Blood Corporation (NYSE:CO) Ratings Coverage

Among 2 analysts covering China Cord Blood (NYSE:CO), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. China Cord Blood had 4 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was downgraded by Howard Weil on Friday, February 5 to “Sector Perform”. The rating was maintained by Roth Capital with “Hold” on Friday, August 28. TH Capital maintained the shares of CO in report on Friday, August 21 with “Neutral” rating. Below is a list of China Cord Blood Corporation (NYSE:CO) latest ratings and price target changes.

The stock decreased 2.09% or $0.22 during the last trading session, reaching $10.31. About 200,305 shares traded. China Cord Blood Corporation (NYSE:CO) has risen 28.22% since December 8, 2016 and is uptrending. It has outperformed by 11.52% the S&P500.

China Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company has market cap of $1.17 billion. The firm offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. It has a 28.56 P/E ratio. As of March 31, 2017, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province.

More notable recent China Cord Blood Corporation (NYSE:CO) news were published by: Prnewswire.com which released: “China Cord Blood Corporation Announces Executive Change” on March 31, 2017, also Seekingalpha.com with their article: “China Cord Blood’s (CO) Management on Q2 2018 Results – Earnings Call Transcript” published on November 21, 2017, Prnewswire.com published: “China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal …” on June 14, 2017. More interesting news about China Cord Blood Corporation (NYSE:CO) were released by: Seekingalpha.com and their article: “China Cord Blood’s (CO) Management on Q1 2018 Results – Earnings Call Transcript” published on August 24, 2017 as well as Prnewswire.com‘s news article titled: “China Cord Blood Corporation Announces Results of 2017 Annual General Meeting” with publication date: December 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: